Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 12
Submit an article Journal homepage
554
Views
11
CrossRef citations to date
0
Altmetric
Letters to the Editor

Is HBV prophylaxis required during CLL treatment with ibrutinib?

Alessandra TedeschiDepartment of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyCorrespondence[email protected]
,
Anna Maria FrustaciDepartment of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
,
Maddalena MazzucchelliDepartment of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
,
Roberto CairoliDepartment of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
&
Marco MontilloDepartment of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
Pages 2966-2968 | Received 12 Jan 2017, Accepted 31 Mar 2017, Published online: 23 May 2017

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

D Sahin Eroglu, K Dalva, A Azap, NY Kutlay, A Ates & MK Yuksel. (2023) Two birds with one stone: a Bruton’s tyrosine kinase inhibitor in a patient with rheumatoid arthritis and 17p + chronic lymphocytic leukaemia. Scandinavian Journal of Rheumatology 52:6, pages 703-704.
Read now
Idanna Innocenti, Francesca Morelli, Francesco Autore, Andrea Corbingi, Raffaella Pasquale, Federica Sorà, Maurizio Pompili & Luca Laurenti. (2019) HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. Leukemia & Lymphoma 60:5, pages 1340-1342.
Read now
Stefano Molica, Luciano Levato, Rosanna Mirabelli, Alessanda Tedeschi & Mirella Lentini. (2018) Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients. Leukemia & Lymphoma 59:11, pages 2734-2736.
Read now

Articles from other publishers (8)

Zheng Yan, Xu-Feng Luo, Shu-Na Yao, Hai-Ying Wang, Jun-Feng Chu, Shuang Zhao, Ming Song, Xu-Dong Wei, Ke-Shu Zhou, Yu-Fu Li, Wen-Ping Zhou, Jiu-Yang Zhang, Pei-Pei Zhang, Li-Li Zhou, Xian-Wei Wang, Zhi-Hua Yao & Yan-Yan Liu. (2023) Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review. Journal of Microbiology, Immunology and Infection.
Crossref
Idanna Innocenti, Gianluigi Reda, Andrea Visentin, Marta Coscia, Marina Motta, Roberta Murru, Riccardo Moia, Massimo Gentile, Elsa Pennese, Francesca Maria Quaglia, Francesco Albano, Ramona Cassin, Marina Deodato, Claudia Ielo, Anna Maria Frustaci, Alfonso Piciocchi, Arianna Rughini, Valentina Arena, Daniela Di Sevo, Annamaria Tomasso, Francesco Autore, Giovanni Del Poeta, Lydia Scarfò, Francesca Romana Mauro, Alessandra Tedeschi, Livio Trentin, Maurizio Pompili, Robin Foà, Paolo Ghia, Antonio Cuneo & Luca Laurenti. (2022) Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. Haematologica 107:6, pages 1470-1473.
Crossref
Sara Kristina Viberg Tjønnfjord, Eirik Brekka Tjønnfjord, Zbigniew Konopski & Geir Erland Tjønnfjord. (2021) Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia. Case Reports in Hematology 2021, pages 1-4.
Crossref
Pier Luigi Zinzani, Alessandro Rambaldi, Gianluca Gaidano, Corrado Girmenia, Monia Marchetti, Fabrizio Pane, Sante Tura & Giovanni Barosi. (2019) Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leukemia Research 81, pages 88-94.
Crossref
Benjamin W. Teh, Constantine S. Tam, Sasanka Handunnetti, Leon J. Worth & Monica A. Slavin. (2018) Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Reviews 32:6, pages 499-507.
Crossref
Anthea C. Peters & Andrei Fagarasanu. (2018) Novel agents in the Canadian therapeutic landscape of chronic lymphocytic leukemia. Oncology Signaling 1:1, pages 7-10.
Crossref
Sarah P. Hammond, Kaiwen Chen, Alisha Pandit, Matthew S. Davids, Nicolas C. Issa & Francisco M. Marty. (2018) Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood 131:17, pages 1987-1989.
Crossref
Jennifer R. Brown. (2018) How I treat CLL patients with ibrutinib. Blood 131:4, pages 379-386.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.